For the year ending 2025-12-31, TSHA made $9,773K in revenue. -$108,995K in net income. Net profit margin of -1115.27%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Revenue | 9,773 | |||
| Research and development | 86,403 | |||
| General and administrative | 33,868 | |||
| Impairment of long-lived assets | 0 | |||
| Total operating expenses | 120,271 | |||
| Loss from operations | -110,498 | |||
| Change in fair value of warrant liability | 1,199 | |||
| Change in fair value of term loan | 6,168 | |||
| Interest income | 9,224 | |||
| Interest expense | 63 | |||
| Other expense | -291 | |||
| Total other income, net | 1,503 | |||
| Net loss | -108,995 | |||
| Basic EPS | -0.34 | |||
| Diluted EPS | -0.34 | |||
| Basic Average Shares | 319,711,972 | |||
| Diluted Average Shares | 319,711,972 | |||
Taysha Gene Therapies, Inc. (TSHA)
Taysha Gene Therapies, Inc. (TSHA)